NewGenIvf Group (NIVF) Stock Falls -59.9% in 30 Days as Dilution and Fundamentals Weigh
Key Takeaways
- NIVF shares fell roughly 59.9% over the 30 days through the August 13, 2026 close, declining from $1.37 to about $0.55.
- The move extends a deeper downtrend, with the stock down approximately 79.6% over the trailing three months.
- Late-July disclosures around the K25.ai follow-on investment, share issuance, and Nasdaq compliance requirements kept dilution concerns in focus.
- Fiscal 2025 revenue declined about 13% to $4.7 million, while operating cash flow remained negative, reinforcing fundamental pressure.
- Micro-cap liquidity and a market capitalization near $3.3 million continue to amplify daily volatility.
Company Overview: NewGenIvf Group’s (NIVF) Focus and Strategy
NewGenIvf Group Limited is a healthcare provider headquartered in Bangkok, Thailand, specializing in assisted reproductive services, including in-vitro fertilization, intracytoplasmic sperm injection, egg donation, surrogacy, and related ancillary care. The company serves patients across Thailand, Cambodia, Hong Kong, and Kyrgyzstan, positioning itself around cross-border fertility and medical-tourism demand in Asia-Pacific. In recent periods, management has repositioned NewGenIvf as a diversified growth company with strategic interests spanning reproductive health, real estate development, and digital-asset and AI-related initiatives. Investors follow the stock for its fertility-services footprint, regional expansion efforts, and its evolving K25.ai and digital-asset strategy, while also weighing its micro-cap size, competitive pressures, and capital needs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Performance: NIVF’s -59.9% Drop Over 30 Days and -79.6% Over the Quarter
Over the 30 days through the August 13, 2026 close, NIVF declined from $1.37 on July 15 to approximately $0.55, a drop of about 59.9%. The move was not a single-day event: the stock printed a series of lower closes through late July and early August, including a decline of roughly 20% between the July 31 close of $0.8184 and the August 3 close of $0.653. The broader trend is even weaker. Over the trailing three months, shares fell about 79.6%, from roughly $2.70 in mid-May to current levels, reflecting persistent selling pressure rather than a short-lived correction. The 52-week range of approximately $0.45 to $513.00 underscores the stock's extreme volatility.
Key Drivers Behind NIVF’s Recent 30-Day Move
The most visible recent catalysts were disclosure-driven rather than earnings-driven. In late July, NewGenIvf announced a follow-on agreement to acquire an additional 3% stake in K25.ai at a $250 million valuation, raising its aggregate ownership to 13%. A subsequent balance-sheet update disclosed that total shares outstanding were expected to reach about 5.9 million following a previously announced issuance of 3,666,667 shares connected to the K25.ai strategy. While management framed the issuance as strengthening market capitalization for Nasdaq compliance, the expanded share count and a market capitalization still in the low single-digit millions left the stock exposed to dilution concerns. The August 3 session's roughly 20% drop highlighted thin liquidity and rapid repricing typical of micro-cap securities. Underlying fundamentals added pressure: fiscal 2025 revenue fell about 13% to $4.7 million, and the company used about $10.9 million in operating activities.
Quarterly Pressures and Strategic Developments for NIVF
The trailing-quarter decline of roughly 79.6% reflects a longer-running tension between strategic optionality and execution risk. During the quarter, NewGenIvf expanded its K25.ai exposure from the initial investment into a position that was revalued as K25.ai completed a Series A round at a $200 million post-money valuation, followed by the additional purchase at a $250 million valuation. The company also highlighted a UAE cytometry venture with an indicated valuation of about $19 million and pursued digital-asset and real-estate initiatives. However, the core fertility business contracted, with revenue down about 13% for fiscal 2025, and operating cash flow remained negative. Investors weighed the potential upside of AI and digital-asset diversification against continued cash burn, recurring share issuance, and Nasdaq listing uncertainty, keeping the stock in a broad downtrend.
What to Watch for NIVF Going Forward
Nasdaq listing compliance remains a central issue, with minimum bid price and market-capitalization thresholds creating a backdrop in which further share issuances are possible. K25.ai's commercialization progress, valuation, and NewGenIvf's ability to realize value from its 13% stake will be closely watched. The UAE/GCC cytometry venture's rollout and the core fertility business, including the next earnings release expected in early September 2026, will test whether revenue can stabilize and cash burn can narrow. Regulatory developments across Thailand, Cambodia, and Kyrgyzstan, medical-tourism demand, and the company's digital-asset exposure add further risk. Investors should also monitor broader sentiment toward micro-cap equities. This information is not investment advice.
Using Tickeron’s Trending AI Robots for Market Insights
In my analysis of volatile names like this, I often turn to Tickeron’s Trending AI Robots page to review curated, data-driven trading strategies. The platform highlights top-performing bots across different styles and timeframes, which can provide additional perspective when evaluating micro-cap equities without relying solely on discretionary views. This section offers a practical way to explore automated approaches suited to shifting market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
NIVF's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for NIVF turned positive on August 07, 2026. Looking at past instances where NIVF's MACD turned positive, the stock continued to rise in of 10 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NIVF advanced for three days, in of 75 cases, the price rose further within the following month. The odds of a continued upward trend are .
NIVF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NIVF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for NIVF entered a downward trend on August 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.121) is normal, around the industry mean (238.724). P/E Ratio (0.005) is within average values for comparable stocks, (131.140). NIVF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.755). NIVF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.014). P/S Ratio (0.010) is also within normal values, averaging (2.678).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NIVF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NIVF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement